Otros idiomas CanSino Biologics Inc.

Acciones

6185

CNE100003F01

Mercado cerrado - Hong Kong S.E. Otros sitios de cotización 10:08:20 26/04/2024			Varia. Cinco días.	Varia. 1 de enero.
18,82 ^HKD	+2,51 %		+14,06 %	-20,08 %

21/03	Cansino Biologics inicia los ensayos clínicos de fase III del fármaco contra el tétanos	MT
20/03	Cansino Biologics Inc. anuncia el inicio del ensayo clínico de fase III y la finalización del primer caso de paciente de prueba para la vacuna antitetánica absorbida	CI

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

CanSinoBIO CSO Shares the Latest Results of the Company's Globally Innovative Pneumococcal Vaccine	26/04
Cansino Bio Gets Nod for China Clinical Trials of Haemophilus Influenzae Vaccine	22/04
Cansino Biologics Pneumococcal Vaccine's Phase I Trial Offers Positive Results	22/04
The Commercialization of Asia's First Meningococcal Conjugate Vaccine From CanSinoBIO Represents a Significant Breakthrough	27/03
CanSino Biologics : CanSinoBIO Initiates Phase Ⅲ Clinical Trial of Group ACYW135 Meningococcal Conjugate Vaccine Menhycia® in Indonesia	25/03
Cansino Biologics Begins Phase III Clinical Trials for Tetanus Drug	21/03
Cansino Biologics Inc. Announces Initiation of Phase III Clinical Trial and Completion of First Trial Patient Case for Absorbed Tetanus Vaccine	20/03
CanSino Biologics Sued by Brazilian Pharma Firm Belcher Over COVID-19 Vaccine Dispute	14/03
Cansino Biologics Inc. Announces Acceptance of Drug Registration Application for 13-Valent Pneumococcal Conjugate Vaccine	28/02
CanSino Biologics' Loss Widens in 2023, Misses EPS, Revenue Estimates; Shares Rise 4%	26/02
Cansino Biologics Inc. Announces Board and Committee Elections	23/02
CanSino Biologics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	23/02
CanSino Biologics Deconsolidates CanSino SPH	02/02
CanSino Biologics' Loss to Widen in 2023; Shares Drop 5%	31/01
CanSino Biologics' 13-Valent Pneumococcal Vaccine Trial Shows Positive Results	31/01
Cansino Biologics Inc. Provides Earnings Guidance for Year Ended December 31, 2023	30/01
CanSino Biologics Inc. Obtains the Final Report of Phase III Clinical Trial Of 13-Valent Pneumococcal Conjugate Vaccine	30/01
CanSino Biologics Enrols First Patient in Australia Clinical Trial of Polio Vaccine	15/01
Cansino Biologics Inc. Announces Phase I Clinical Trial and Completion of First Patient Case for Recombinant Poliomyelitis Vaccine	15/01
Sinovac Halts Production of COVID-19 Vaccine as Demand Wanes	12/01

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Filtros

Titulares

ENTREVISTA - Xuefeng Yu, CEO de CanSino Biologics: Entre bastidores del acuerdo con AstraZeneca

31 de agosto 2023 a las 12:08